2nd Gene Therapy Analytical Development Summit

Memo

In the context of rapid gene therapy progress and mounting regulatory scrutiny, the 2nd Annual Gene Therapy Analytical Development Summit will unite virtually large pharma and innovative biotechs to discuss the full and comprehensive range of analytical tools required to guarantee the consistency, quality and safety of gene therapy products. Focused specifically on addressing the unique analytical challenges posed by gene therapy vectors, this technical scientific conference will unite the Analytical Development, QC, CMC, and Process Development leaders grappling with these challenges first-hand. Incorporating tracks taking a deep dive into bioassays, molecular biology, and analytical chemistry, this is your opportunity to gain extensive technical information enabling you to solve the exact challenges you're encountering. Enhance your existing analytical methods and explore innovative novel tools to support safe and effective gene therapy development. View the full event guide to learn more: https://ter.li/1z94y0 URLs:Tickets: https://go.evvnt.com/663255-2?pid=5569 Sponsor: https://go.evvnt.com/663255-3?pid=5569 Date and Time: On Monday November 30, 2020 at 10:00 am ends Thursday December 03, 2020 at 6:00 pm Prices:DIGITAL Super Earlybird Registration: 2 Day Conference + Workshop Day AND Discussion Day: USD 3305.00,DIGITAL Super Earlybird Registration: 2 Day Conference + Workshop Day OR Discussion Day: USD 2527.00,DIGITAL Super Earlybird Registration: 2 Day Conference: USD 1749.00,DIGITAL Standard Rate Registration: 2 Day Conference + Workshop Day AND Discussion Day: USD 3585.00,DIGITAL Standard Rate Registration: 2 Day Conference + Workshop Day OR Discussion Day: USD 2807.00,DIGITAL Standard Rate Registration: 2 Day Conference: USD 2029.00 Speakers: Yuan Zhao, Leader of Gene Therapy Section, Advanced Therapy Division/NIBSC, MHRA, Claire Davies, Head of Bioanalytics, Sanofi, Michael Byrne, Senior Director, Analytical Development and Product Quality, REGENXBIO, Barbara Bonamassa, Quality Assessor and European Medicines Agency (EMA) Expert for ATMPs, AIFA, Sushmita 'Mimi' Roy, Executive Director, Analytical Sciences, Process Sciences, BioMarin, Julia Wang, Associate Director, Analytical Development - Analytical Chemistry, AveXis, Herbert Runnels, Senior Research Fellow, Gene Therapy Global Analytical Sponsor, Pfizer, Mark Galbraith, Head of Quality Control and Analytical Sciences, Spark Therapeutics, Fengrong Zuo, Senior Director, CMC Regulatory Quality and Analytical Development, AveXis, Uditha DeAlwis, Executive Director, Analytical Sciences, Sarepta Therapeutics